CN101213454A - 用于癌症风险评估的膜联蛋白 - Google Patents

用于癌症风险评估的膜联蛋白 Download PDF

Info

Publication number
CN101213454A
CN101213454A CNA2006800238831A CN200680023883A CN101213454A CN 101213454 A CN101213454 A CN 101213454A CN A2006800238831 A CNA2006800238831 A CN A2006800238831A CN 200680023883 A CN200680023883 A CN 200680023883A CN 101213454 A CN101213454 A CN 101213454A
Authority
CN
China
Prior art keywords
annexin
abundance
cancer
cell
psa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800238831A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡希尔
A·施拉坦霍尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoSys AG
Original Assignee
ProteoSys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoSys AG filed Critical ProteoSys AG
Publication of CN101213454A publication Critical patent/CN101213454A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800238831A 2005-05-21 2006-05-22 用于癌症风险评估的膜联蛋白 Pending CN101213454A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011042.8 2005-05-21
EP05011042A EP1724585A1 (fr) 2005-05-21 2005-05-21 Annexin pour l'évaluation du risque de cancer
EP05026092.6 2005-11-30

Publications (1)

Publication Number Publication Date
CN101213454A true CN101213454A (zh) 2008-07-02

Family

ID=34936793

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800238831A Pending CN101213454A (zh) 2005-05-21 2006-05-22 用于癌症风险评估的膜联蛋白

Country Status (4)

Country Link
US (1) US7732148B2 (fr)
EP (1) EP1724585A1 (fr)
CN (1) CN101213454A (fr)
ES (1) ES2362512T3 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317785A (zh) * 2009-02-04 2012-01-11 国立大学法人东京工业大学 Psa的分析方法、以及使用上述分析方法的前列腺癌和前列腺肥大症的鉴别方法
CN103116028A (zh) * 2011-11-17 2013-05-22 上海市公共卫生临床中心 膜联蛋白a3在检测酒精性肝纤维化中的用途
US9285368B2 (en) 2009-10-30 2016-03-15 Tokyo Institute Of Technology Method for analyzing PSA, and a method for distinguishing prostate cancer from prostatic hypertrophy using that method for analyzing PSA
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物
CN109557311A (zh) * 2018-12-13 2019-04-02 中南大学湘雅医院 结直肠癌诊断标志物及结直肠癌的检测产品及其应用
CN109789208A (zh) * 2016-07-26 2019-05-21 新加坡科技研究局 抗膜联蛋白a2单克隆抗体
CN112578125A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备卵巢病变筛查试剂盒中的用途
CN112578123A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
CN112578122A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1724586A3 (fr) * 2005-05-21 2007-07-04 ProteoSys AG Annexine pour l'évaluation du risque de cancer
US7742148B2 (en) * 2005-06-08 2010-06-22 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method for writing a digital image
RU2467335C2 (ru) * 2006-06-09 2012-11-20 Протеосис Аг Моноклональные антитела против аннексина а3 для обнаружения карциномы простаты
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
CA2733672C (fr) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Microvesicules issues d'une cellule tumorale
CA2701341C (fr) * 2007-11-20 2012-03-20 Johann Karl Procede de detection du cancer colorectal a partir d'un echantillon de selles au moyen d'une combinaison de marqueurs associant la calprotectine et le complexe hemoglobine/haptoglobine
WO2010036924A2 (fr) * 2008-09-25 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Healthe And Human Serv. Gènes inflammatoires et micro-arn 21 utilisables en tant que biomarqueurs dans le pronostic en matière de cancer du colon
CA2739445A1 (fr) 2008-10-03 2010-04-08 Advanced Proteome Therapeutics, Inc. Modifications de n-terminaux specifiques de site de proteines et formation de conjugue
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
TWI387750B (zh) * 2009-02-10 2013-03-01 Nat Defense Medical Ct Biomarker and detection method for detecting kidney disease
WO2010120686A2 (fr) * 2009-04-13 2010-10-21 Parsons J Kellogg Procédés destinés au diagnostic et au traitement de l'hyperplasie bénigne de la prostate
US10265068B2 (en) 2015-12-30 2019-04-23 Ethicon Llc Surgical instruments with separable motors and motor control circuits

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2002012280A2 (fr) * 2000-08-03 2002-02-14 Corixa Corporation Compositions et procedes pour le diagnostic et le traitement du cancer du colon
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
WO2002082076A2 (fr) * 2001-04-03 2002-10-17 Merck Patent Gmbh Marqueurs d'hypernephromes
US20030108963A1 (en) * 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
WO2003058201A2 (fr) * 2001-12-31 2003-07-17 Quark Biotech, Inc. Procedes permettant d'identifier des genes marqueurs pour le cancer
EP1953244A1 (fr) * 2002-01-09 2008-08-06 Nakamura, Yusuke Profils de cancer
EP2295976A1 (fr) * 2003-03-08 2011-03-16 Auvation Ltd Marqueurs du cancer colorectal
PL1720611T3 (pl) 2004-02-16 2010-09-30 Proteosys Ag Marker diagnostyczny dla raka

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317785B (zh) * 2009-02-04 2015-01-14 国立大学法人东京工业大学 Psa的分析方法、以及使用上述分析方法的前列腺癌和前列腺肥大症的鉴别方法
CN102317785A (zh) * 2009-02-04 2012-01-11 国立大学法人东京工业大学 Psa的分析方法、以及使用上述分析方法的前列腺癌和前列腺肥大症的鉴别方法
US10866240B2 (en) 2009-02-04 2020-12-15 Konica Minolta, Inc. Method for analyzing PSA and method for distinguishing prostate cancer from prostatic hypertrophy using that method for analyzing PSA
US9285368B2 (en) 2009-10-30 2016-03-15 Tokyo Institute Of Technology Method for analyzing PSA, and a method for distinguishing prostate cancer from prostatic hypertrophy using that method for analyzing PSA
US10196694B2 (en) 2009-10-30 2019-02-05 Tokyo Institute Of Technology Method for analyzing PSA, and a method for distinguishing prostate cancer from prostatic hypertrophy using that method for analyzing PSA
CN103116028A (zh) * 2011-11-17 2013-05-22 上海市公共卫生临床中心 膜联蛋白a3在检测酒精性肝纤维化中的用途
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物
CN109789208B (zh) * 2016-07-26 2023-03-03 新加坡科技研究局 抗膜联蛋白a2单克隆抗体
CN109789208A (zh) * 2016-07-26 2019-05-21 新加坡科技研究局 抗膜联蛋白a2单克隆抗体
CN109557311A (zh) * 2018-12-13 2019-04-02 中南大学湘雅医院 结直肠癌诊断标志物及结直肠癌的检测产品及其应用
CN112578123A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
CN112578122A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途
CN112578122B (zh) * 2019-09-27 2022-08-02 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备畸形精子症筛查试剂盒中的用途
CN112578125A (zh) * 2019-09-27 2021-03-30 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备卵巢病变筛查试剂盒中的用途

Also Published As

Publication number Publication date
EP1724585A1 (fr) 2006-11-22
US20080200385A1 (en) 2008-08-21
ES2362512T3 (es) 2011-07-06
US7732148B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
CN101213454A (zh) 用于癌症风险评估的膜联蛋白
US8409812B2 (en) Annexin A3 for cancer diagnosis
Schreuders et al. Advances in fecal tests for colorectal cancer screening
Modlin et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies
Costa et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation
RU2460075C2 (ru) Биомаркеры рака
Yip-Schneider et al. Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts
Zahr et al. Malignancy in myositis
Baak et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression
Kuiken et al. Biomarkers and non-invasive tests for gastrointestinal mucositis
CN102625914A (zh) 检测膀胱癌或者膀胱癌风险的方法
CN101449163A (zh) S100a12蛋白作为结肠直肠癌标记的用途
Magnason et al. Prevalence and progression of CRF in Iceland: a population-based study
Dai et al. Fecal markers in the management of inflammatory bowel disease
EP2948769B1 (fr) Biomarqeurs de plaquettes utilisés dans le diagnostic du cancer
CN101680898A (zh) Timp-1作为结肠直肠癌标志的用途
Ge et al. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Abdulganieva et al. Faecal Neutrophil Gelatinase-associated Lipocalin as a Non-invasive Biomarker in Inflammatory Bowel Disease
Jianguo et al. Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in children
EP2793028B1 (fr) Thiorédoxine comme marqueur diagnostique du cancer de l'ovaire
JP2021038990A (ja) 大腸がん罹患のリスクを評価するための方法
CN107345967A (zh) Gp73蛋白作为血清标记物在诊断癌症中的用途
US20130157292A1 (en) Composition for the diagnosis of ovarian cancer or pneumonia comprising thioredoxin 1 as active ingredient and use thereof
WO2022084518A1 (fr) Microvésicules circulantes exprimant l'anhydrase carbonique 9 pour le pronostic du carcinome des cellules rénales

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080702